Trexquant Investment’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Trexquant Investment’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,016	Closed	-$135K	–	1696
2021 Q3	$135K	Sell	3,016 -352	-10%	-$17.2K	0.01%	1021
2021 Q2	$184K	Buy	3,368 +1,665	+98%	+$98.5K	0.02%	933
2021 Q1	$127K	Sell	1,703 -258	-13%	-$26.8K	0.01%	1034
2020 Q4	$213K	Buy	+1,961	New	+$179K	0.02%	864
2020 Q1	–	Sell	-1,335	Closed	-$92K	–	1481
2019 Q4	$92K	Buy	+1,335	New	+$81K	0.01%	983
2019 Q1	–	Sell	-4,159	Closed	-$232K	–	1374
2018 Q4	$232K	Buy	+4,159	New	+$316K	0.01%	865
2017 Q4	–	Sell	-1,914	Closed	-$282K	–	1293
2017 Q3	$282K	Buy	+1,914	New	+$360K	0.07%	487

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Trexquant Investment's SYRS Position: Q4 2021 in Review

Trexquant Investment sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2021, closing a stake of 3,016 shares — an estimated $135K sold.

Trexquant Investment first reported a position in SYRS in Q3 2017 and held it in 7 quarters. The position peaked at $282K in Q3 2017. 90 funds tracked by Wall St. Rank hold SYRS as of Q4 2021.

Trexquant Investment reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Trexquant Investment sold 3,016 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $135K.
Trexquant Investment first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 7 quarters.
Trexquant Investment's Syros Pharmaceuticals, Inc. Common Stock position peaked at $282K in Q3 2017.
90 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Trexquant Investment's 13F filing for Q4 2021, filed 14 Feb 2022.